Proactive Investors - Run By Investors For Investors

Telix Pharmaceuticals nearing revenue generation as M&A activity in sector heats up

Telix Pharmaceuticals Ltd. (ASX:TLX) CEO Dr. Christian Behrenbruch updates Proactive Investors on focus and achievements since the company listed on the ASX in November 2017.

Telix is establishing a pipeline of oncology programmes at varying stages of development in multiple international markets, with revenue generation in sight for some of the more advanced projects.

View full TLX profile View Profile

Telix Pharmaceuticals Ltd Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use